Pharma M&A: Big Deals of Early 2024
The first half of 2024 has been transformative for the pharmaceutical sector, highlighted by major acquisition deals. Key players such as Sun Pharma, AstraZeneca, Bayer, and Novo Nordisk have strategically expanded their portfolios through significant mergers and acquisitions, reshaping the industry landscape.
This article delves into the noteworthy acquisition deals that have defined the first half of the year:
Unlock the Future of Digital Health — Free for 60 Days!
Join DHN Plus and access exclusive news, intelligence reports, and deep-dive research trusted by healthtech leaders.
Already a subscriber? Log in
Subscribe Now @ ₹499.00Stay tuned for more such updates on Digital Health News
Follow us
